PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

PTC Therapeutics (PTCT) Misses Q2 EPS by 17c, Revenues Beat

August 6, 2019 5:25 PM EDT

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.75), $0.17 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $85.5 million versus the consensus estimate of $78.64 million.

Second quarter 2019 financial highlights:

Total revenues were $85.5 million for the second quarter of 2019, compared to $68.7 million for the second quarter of 2018.Translarna net product revenues were $57.8 million for the second quarter of 2019, compared to $47.8 million for the second quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza net product revenues were $27.6 million for the second quarter of 2019, compared to... More